|
Name |
(1R,5R)-1,8-Dimethyl-4-(propan-2-ylidene)spiro[4.5]dec-7-ene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(1R,5R)-1,8-dimethyl-4-propan-2-ylidenespiro[4.5]dec-8-ene
|
|
SMILES |
C[C@@H]1CCC(=C(C)C)[C@@]12CCC(=CC2)C
|
|
InChI |
InChI=1S/C15H24/c1-11(2)14-6-5-13(4)15(14)9-7-12(3)8-10-15/h7,13H,5-6,8-10H2,1-4H3/t13-,15+/m1/s1
|
|
InChIKey |
HMKLOOMRRZKSNM-HIFRSBDPSA-N
|
|
Synonyms |
.beta.-alaskene; delta-Acoradiene; (.+/-.)-.beta.-Alaskene; (1R,5R)-1,8-Dimethyl-4-(propan-2-ylidene)spiro[4.5]dec-7-ene; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, cis-; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, (1R,5R)-rel-; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, cis-(.+/-.)-; 28400-13-7
|
|
CAS | NA | |
PubChem CID | 6428281 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.6 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.472 |
Caco-2 Permeability: | -4.449 | MDCK Permeability: | 0.00001490 |
Pgp-inhibitor: | 0.12 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.97 |
30% Bioavailability (F30%): | 0.579 |
Blood-Brain-Barrier Penetration (BBB): | 0.102 | Plasma Protein Binding (PPB): | 95.84% |
Volume Distribution (VD): | 5.522 | Fu: | 3.14% |
CYP1A2-inhibitor: | 0.753 | CYP1A2-substrate: | 0.474 |
CYP2C19-inhibitor: | 0.58 | CYP2C19-substrate: | 0.903 |
CYP2C9-inhibitor: | 0.509 | CYP2C9-substrate: | 0.84 |
CYP2D6-inhibitor: | 0.062 | CYP2D6-substrate: | 0.317 |
CYP3A4-inhibitor: | 0.172 | CYP3A4-substrate: | 0.215 |
Clearance (CL): | 10.267 | Half-life (T1/2): | 0.173 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.249 |
Drug-inuced Liver Injury (DILI): | 0.045 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.019 | Maximum Recommended Daily Dose: | 0.047 |
Skin Sensitization: | 0.905 | Carcinogencity: | 0.268 |
Eye Corrosion: | 0.819 | Eye Irritation: | 0.975 |
Respiratory Toxicity: | 0.088 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000786 | 0.464 | D04SFH | 0.225 | ||||
ENC002392 | 0.464 | D0I2SD | 0.225 | ||||
ENC002990 | 0.390 | D04GJN | 0.225 | ||||
ENC000395 | 0.388 | D0V2JK | 0.223 | ||||
ENC001077 | 0.377 | D07BSQ | 0.221 | ||||
ENC001135 | 0.367 | D02CNR | 0.216 | ||||
ENC000588 | 0.367 | D0W6DG | 0.207 | ||||
ENC001637 | 0.346 | D0F1UL | 0.207 | ||||
ENC000388 | 0.346 | D0Z1XD | 0.200 | ||||
ENC003255 | 0.344 | D0F2AK | 0.200 |